Celator Pharmaceuticals (CPXX) 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 08, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'CPXX	'
Entity Common Stock, Shares Outstanding	'	26,078,532
Entity Registrant Name	'Celator Pharmaceuticals Inc	'
Entity Central Index Key	'0001327467	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$24,924,518	$23,589,516
Restricted cash	287,562	287,657
Other receivables	3,328	1,417,313
Prepaid expenses and deposits	599,021	491,465
Assets held for sale	74,086	74,086
Other current assets	879,056	468,389
Total current assets	26,767,571	26,328,426
Property and equipment, net	1,046,486	1,138,579
Other assets	653,299	5,745
Total assets	28,467,356	27,472,750
Current liabilities:	'	'
Current portion of long-term debt	282,253	0
Accounts payable	525,400	1,193,148
Accrued liabilities	1,545,943	1,630,809
Current portion of deferred revenue	542,986	542,986
Total current liabilities	2,896,582	3,366,943
Long-term debt	9,744,407	0
Deferred revenue	316,743	588,236
Deferred rent	49,844	53,084
Total liabilities	13,007,576	4,008,263
Stockholders' equity	'	'
Preferred stock Authorized 20,000,000 shares, par value $0.001	0	0
Common stockAuthorized 200,000,000 shares, par value $0.001Issued and outstanding 26,078,532 and 26,035,596 shares as of June 30, 2014 and December 31, 2013 respectively	26,079	26,036
Warrants	1,083,193	1,083,193
Additional paid-in capital	157,017,839	155,953,894
Accumulated other comprehensive loss	-1,133,266	-1,133,266
Accumulated deficit	-141,534,065	-132,465,370
Total stockholders' equity	15,459,780	23,464,487
Total liabilities and stockholders' equity	$28,467,356	$27,472,750

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred Stock, Shares Authorized	20,000,000	20,000,000
peferred stock, par valur (in dollars per share)	$0.00	$0.00
Common stock, authorized shares	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, issued shares	26,078,532	26,035,596
Common stock, outstanding shares	26,078,532	26,035,596

Consolidated_Statements_of_Los

Consolidated Statements of Loss (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Expenses	'	'	'	'
Research and development	$2,936,114	$2,018,566	$5,903,967	$3,669,975
Leukemia & Lymphoma Society funding	-135,746	-135,747	-771,493	-289,593
General and administrative	1,729,101	1,138,649	3,617,368	2,487,648
Loss on disposal of property and equipment	0	124,965	0	138,692
Amortization and depreciation	48,353	49,464	96,088	97,052
Operating loss	-4,577,822	-3,195,897	-8,845,930	-6,103,774
Other income (expenses)	'	'	'	'
Foreign exchange (loss) gain	-14,605	-1,435	-26,313	-4,484
Interest and miscellaneous income	1,942	3,037	4,257	3,466
Non-cash derivative instrument charge	0	-747,311	0	-7,473,108
Interest expense	-200,709	-99,371	-200,709	-147,025
Net loss	($4,791,194)	($4,040,977)	($9,068,695)	($13,724,925)
Net loss per share	'	'	'	'
Basic and diluted (in dollars per share)	($0.18)	($0.18)	($0.35)	($0.77)
Weighted average of common shares outstanding	'	'	'	'
Basic and diluted (in shares)	26,078,532	22,089,921	26,058,131	17,904,791

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	COMMON STOCK [Member]	WARRANTS [Member]	ADDITIONAL PAID-IN CAPITAL [Member]	ACCUMULATED OTHER COMPREHENSIVE LOSS [Member]	ACCUMULATED DEFICIT [Member]
Balance at Dec. 31, 2013	$23,464,487	$26,036	$1,083,193	$155,953,894	($1,133,266)	($132,465,370)
Balance (in shares) at Dec. 31, 2013	'	26,035,596	'	'	'	'
Exercise of stock options	100,639	43	0	100,596	0	0
Exercise of stock options (in shares)	42,936	42,936	'	'	'	'
Stock based compensation	642,597	0	0	642,597	0	0
Warrants issued	320,752	0	0	320,752	0	0
Net loss for the period	-9,068,695	0	0	0	0	-9,068,695
Balance at Jun. 30, 2014	$15,459,780	$26,079	$1,083,193	$157,017,839	($1,133,266)	($141,534,065)
Balance (in shares) at Jun. 30, 2014	'	26,078,532	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Operating activities	'	'
Net loss	($9,068,695)	($13,724,925)
Adjustments to reconcile net loss to net cash used in operating activities	'	'
Amortization and depreciation	96,088	97,052
Non-cash stock-based compensation expense	642,597	86,780
Loss on disposal of property and equipment	0	138,692
Non-cash derivative instrument charge	0	7,473,108
Non-cash financing costs	57,167	74,752
Changes in operating assets and liabilities	'	'
Other receivables	1,410,237	1,993,925
Prepaid expenses and deposits	-107,135	-140,756
Restricted cash	-25	-250,022
Other current assets	-410,667	-358,359
Accounts payable	-666,455	-49,184
Accrued liabilities	-83,059	-42,816
Deferred rent	-3,240	0
Deferred revenue	-271,493	-289,593
Cash used in operating activities	-8,404,680	-4,991,346
Investing activities	'	'
Purchase of property and equipment	-3,995	-35,544
Proceeds on disposals of property and equipment	0	36,673
Cash (used in) provided by investing activities	-3,995	1,129
Financing activities	'	'
Proceeds from issuance of common stock and on options exercised	104,387	32,499,986
Payment of share issuance costs	0	-3,079,611
Proceeds from loans payable	9,827,216	0
Payment of debt issuance costs	-184,469	0
Repayments of loans payable	0	-3,000,000
Cash provided by financing activities	9,747,134	26,420,375
Effect of foreign exchange rate changes	-3,457	1,707
Net change in cash and cash equivalents	1,335,002	21,431,865
Cash and cash equivalents, beginning of period	23,589,516	9,648,008
Cash and cash equivalents, end of period	24,924,518	31,079,873
Supplemental disclosure of cash flow information	'	'
Interest paid	62,292	79,388
Capital expenditure incurred but not paid	$0	$14,687

Nature_of_Business_and_Liquidi

Nature of Business and Liquidity	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Nature of Operations [Text Block]	'
	1	Nature of Business and Liquidity
	Celator Pharmaceuticals, Inc. (“CPI” or the “Company”), with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the Company’s proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes.
	The Company has incurred recurring losses and negative cash flows from operations since inception. As of June 30, 2014, the Company had an accumulated deficit of $141.5 million. The Company expects operating losses and negative cash flows to continue for the foreseeable future until such time, if ever, that it can generate significant revenues from its product candidates currently in development. At June 30, 2014, the Company had cash and cash equivalents of $24.9 million. Management believes that the cash and cash equivalents at June 30, 2014 will be sufficient to meet estimated working capital requirements and fund planned operations into the fourth quarter of 2015. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates.
	The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
		2	Summary of Significant Accounting Policies
	The accompanying unaudited consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the consolidated financial statements and notes included in Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted.
	In the opinion of management of the Company, the interim consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the financial position, operating results and cash flows of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
	Basis of consolidation: The consolidated financial statements include the accounts of Celator and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.
	Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, among other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.
	New Accounting Pronouncement: In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-10, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminates all incremental financial reporting requirements for development stage entities by removing Accounting Standards Codification (ASC) Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. The amendments in this Update remove the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASC Topic 915 is removed effective for annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of its June 30, 2014 financial statements.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
		3	Fair Value Measurements
	Financial instruments of the Company consist of cash deposits, money market investments, other receivables, accounts payable, certain accrued liabilities and debt. The carrying value of these financial instruments generally approximates fair value due to their short-term nature.
	ASC Topic 820, Fair Value Measurements establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820-10 establishes three levels of inputs that may be used to measure fair value:
	Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
	Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
	Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
	ASC 820 requires disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures regarding the level of disaggregation and the inputs and valuation techniques used to measure fair value.
	The Company recognizes transfers between input levels as of the actual date of event. There were no transfers between levels and the following table provides the assets carried at fair value:
			Fair Value		(Level 1)		(Level 2)		(Level 3)
	June 30, 2014
	Assets:
	Certificates of Deposit		$	14,003,243	$	14,003,243	$	-	$	-
	Money Market Fund			8,308,322		8,308,322		-		-
	Total		$	22,311,565	$	22,311,565	$	-	$	-
	31-Dec-13
	Assets:
	Certificates of Deposit		$	15,003,472	$	15,003,472	$	-	$	-
	Money Market Fund			7,597,730		7,597,730		-		-
	Total		$	22,601,202	$	22,601,202	$	-	$	-
	Non-cash derivative instrument charge
	The Company recognized a non-cash derivative instrument charge of $747,311 and $7,473,108 during the three and six months ended June 30, 2013 respectively. The charge related to an obligation to issue additional shares of common stock and warrants to certain existing stockholders who participated in early closings of a private placement that started in 2012 and closed on April 29, 2013. The fair value of these common shares and warrants was recognized as a derivative liability with a corresponding charge to the statement of loss. Upon the closing of the April 2013 Private Placement, the derivative liability was reclassified into stockholders’ equity as the obligation to issue additional securities no longer existed. This contractual obligation was fair valued using significant unobservable inputs (Level 3).

Other_Receivables

Other Receivables	6 Months Ended
	Jun. 30, 2014
Other Receivables, Net, Current [Abstract]	'
Other Receivable [Text Block]	'
	4	Other Receivables
	Other receivables as of June 30, 2014 and December 31, 2013, consists of the following:
			June 30, 2014		December 31, 2013
	Receivables related to the sale of New Jersey net operating losses		$	-	$	1,412,302
	Other receivables			3,328		5,011
			$	3,328	$	1,417,313

Other_Current_Assets

Other Current Assets	6 Months Ended
	Jun. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Other Current Assets [Text Block]	'
	5	Other Current Assets
	Other current assets as of June 30, 2014 and December 31, 2013 consist of the following:
			June 30, 2014		December 31, 2013
	Clinical trial materials		$	879,056	$	468,389

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Property Plant And Equipment Disclosure [Text Block]	'
		6	Property and Equipment
	Property and equipment as of June 30, 2014 and December 31, 2013 including assets held under capital lease, consists of the following:
			June 30, 2014		December 31, 2013
	Computer and equipment		$	140,495	$	136,498
	Furniture and office equipment			96,457		96,457
	Laboratory equipment			1,760,633		1,760,633
	Capital lease equipment			155,523		155,523
	Leaseholds			37,789		37,789
				2,190,897		2,186,900
	Less: Accumulated depreciation			-1,144,411		-1,048,321
			$	1,046,486	$	1,138,579
			Three months ended				Six months ended
			June 30				June 30
			2014		2013		2014		2013
	Depreciation and amortization		$	48,353	$	49,464	$	96,088	$	97,052
	In February 2012, the Company closed a laboratory in Canada and consigned certain property and equipment for sale with net book value of $507,622. At June 30, 2014 and December 31, 2013, the net book value of the remaining consigned equipment was $74,086 and consisted solely of scientific equipment, which is presented as assets held for sale on the consolidated balance sheet.
	During six months ended June 30, 2013 assets held for sale with a net book value of $174,768 were sold for proceeds of $36,673 resulting in a loss on disposal of $138,095. There were no disposals during the three and six months ended June 30, 2014.

Accrued_Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2014
Payables And Accruals [Abstract]	'
Accounts Payable And Accrued Liabilities Disclosure [Text Block]	'
		7	Accrued Liabilities
	Accrued liabilities as of June 30, 2014 and December 31, 2013 consist of the following:
			June 30, 2014		December 31, 2013
	Accrued bonuses		$	562,392	$	624,472
	Accrued salaries and vacation			176,836		143,484
	Accrued professional fees			30,000		30,911
	Accrued clinical trial expenses			631,023		636,497
	Accrued trade payables other			145,692		195,445
			$	1,545,943	$	1,630,809

Loans_Payable

Loans Payable	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
		8	Loans Payable
	On May 9, 2014, the Company entered into a term loan agreement for $15 million with Hercules Technology Growth Capital, Inc. The first $10 million of the term loan was funded at closing, and is repayable in installments over forty-two months including an initial interest-only period of twelve months after closing. The remaining $5 million of the term loan can be drawn down at the Company’s option at any time between December 15, 2014 and March 31, 2015. Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period extendable to December 1, 2015, contingent upon achieving full enrollment of the CPX-351 Phase 3 study by December 31, 2014. The funds will be used to provide general working capital.
	Pursuant to the loan agreement, the Company issued Hercules a warrant to purchase 158,006 shares of the Company’s common stock at an exercise price of $2.67 per share with a term of five years. The fair value of the warrants of $320,752 and financing costs of $357,253 incurred in connection with the term loan were recorded as debt issuance costs and will be amortized as interest expense using the effective interest method over the term of the loan. Amortization of debt issuance costs was $30,507 for the three and six months ended June 30, 2014 and the remaining unamortized debt issuance costs of $647,498 is included in other non-current assets.
	In addition, the Company will pay an end of term charge of $592,500 on the earliest to occur of (i) the term loan maturity date, (ii) the date that the Company prepays the outstanding loan, or (iii) the date that the loan become due and payable. The end of term charge will be accrued as additional interest expense using the effective interest rate method over the term of the loan. The Company accrued $26,660 of this fee during the three months ended June 30, 2014.
	Long-term debt as of June 30, 2014 consists of the following:
	Loan payable		$	10,000,000
	End of term fee			26,660
				10,026,660
	Less: Current portion			-282,253
	Long-term debt		$	9,744,407

Stock_Based_Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
		9	Stock Based Compensation
	The following table summarizes the activity of the Company’s stock option plans for the six months ended June 30, 2014:
			Number of		Exercise
			options		price
	31-Dec-13		2,578,252		$	2.98
	Granted		478,500			3.15
	Exercised		-42,936			2.34
	Cancelled		-9,269			3.37
	30-Jun-14		3,004,547		$	3.02
	Exercisable at June 30, 2014		1,094,447		$	2.72
	The following table provides information regarding stock options activity during the periods:
			Three months ended							Six months ended
			June 30							June 30
			2014				2013			2014			2013
	Stock compensation expense recognized		$	339,615			$	82,502		$	642,597		$	86,780
	Weighted average grant-date fair value of stock options issued (per share)		$	2.35			$	2.14		$	2.7		$	2.14
	Grant-date fair value of stock options issued		$	197,400			$	3,268,101		$	1,291,950		$	3,268,101
	Volatility			112	%			118.2	%		114.5	%		118.2	%
	Risk-free interest rate			1.9	%			1.9	%		2	%		1.9	%
	Dividend yield			0	%			0	%		0	%		0	%
	Expected life in years			6				6.2			6.2			6.2
	Intrinsic value of stock options exercised		$	-			$	-		$	38,892		$	-
	The grant-date fair value of stock options is estimated using the Black Scholes option pricing model. The Company determined the options’ life based on the simplified method and determined the options’ expected volatility based on peer group volatility and dividend yield based on the historical dividend payments. The risk free interest rate is based on the yield of an applicable term Treasury instrument.
	The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. At June 30, 2014, the total compensation cost related to non-vested awards not yet recognized and weighted average period over which it will be recognized was $4,297,202 and 3.1 years, respectively.

Geographic_Segment_Information

Geographic Segment Information	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	10	Geographic Segment Information
	The Company operates in the United States and Canada. The Company’s CPX-351 clinical trial materials are manufactured by a third party using the Company’s equipment located in Germany. Geographic net loss information is based on the location whereby the expenses were incurred. The geographic information about total assets is based on the physical location of the assets.
			Total Assets
			June 30, 2014		December 31, 2013
	United States		$	27,301,017	$	26,190,516
	Canada			242,462		284,563
	Germany			923,877		997,671
	Total Assets		$	28,467,356	$	27,472,750
					Net Loss
			Three months ended				Six months
			June 30				June 30
			2014		2013		2014		2013
	United States			-4,276,673		-3,624,723		-7,931,554		-12,374,358
	Canada			-514,521		-416,254		-1,137,141		-1,350,567
	Total Net Loss		$	-4,791,194	$	-4,040,977	$	-9,068,695	$	-13,724,925

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments And Contingencies Disclosure [Text Block]	'
		11	Commitments and Contingencies
	In February 2013, the Company renewed its office lease agreements for office space in Vancouver, British Columbia, effective April 1, 2013, which expires in June 2016. The remaining minimum lease payments as of June 30, 2014 totaled $133,439.
	In March 2013, the Company entered into an office lease agreement for office space in Ewing, New Jersey, which commenced in June 2013 with a term of sixty months. The remaining minimum lease payments as of June 30, 2014 totaled $564,624. Under the Ewing, New Jersey lease agreement, the Company will be obligated to maintain a letter of credit from a bank with respect to its security deposit obligations in the amount of $200,000 during the first year of the Agreement, which amount will be reduced by $40,000 per year on each of December 1, 2014, 2015, and 2016 and by $60,000 on December 1, 2017.
	The Company has a worldwide exclusive license agreement with Princeton University dated June 2007 that provides the Company with exclusive rights to some aspects of its nanoparticle polymer technology arising from research sponsored by the Company at Princeton University between 2003 and 2007. These inventions are generally characterized as particulate constructs for release of active agents for medical application. Of the products currently in Celator’s pipeline, only the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation is subject to this agreement. The Company is obligated to pay a royalty on net sales to Princeton University of a low single-digit percentage if any invention is sold by the Company or a company to which the product covered by the invention was licensed by the Company, which was generated under the exclusive licensing agreement. No royalty or other product/sub-license-related payments have been made to date. The Company is obligated to provide Princeton University a percentage within the range of 45% to 55% of proceeds obtained from a sub-license of the intellectual property to a third party in cases where the Company has not conducted any research or development activities and is solely licensing out the original intellectual property jointly developed by the Company and Princeton University. The Company may terminate the agreement at any time by giving 90 days written notice to Princeton University. Princeton may terminate the agreement if the Company should breach or fail to perform under the agreement, with written notice of default provided by Princeton University to the Company and only if the Company fails to cure the default within 60 days. The Company is obligated under the agreement to provide an annual progress report to Princeton University on any developments of the licensed technology as well as prosecution of the patents covering the technology and the use of commercially reasonable efforts to develop licensed products.
	The Company has a collaborative research agreement dated May 2001 with the British Columbia Cancer Agency (“BCCA”) whereby in consideration for the license and conditional assignment of all Company-sponsored intellectual property to the Company by BCCA, the Company will pay to BCCA a royalty in the low single digits on net sales of royalty-bearing products in territories so long as a valid claim exists for inventions made between June 2000 and June 2005 under the agreement. All obligations relating to the conduct of the research and assignment of intellectual property have been completed. No payments of royalties have been made to date. Either party may terminate the agreement if the other party commits a material breach or default and such breach or default is not reasonably cured within 45 days.
	In consideration of funding by the Leukemia & Lymphoma Society ® (“LLS”) and transfer to the Company of any rights LLS may have to any project inventions developed during the term of the agreement, the Company may be required to pay LLS a cash multiple on the LLS funding, (LLS funding is the $5 million in support of the Phase 3 study in addition to the approximately $4.1 million the Company received in support of the Phase 2 study). Subject to exclusions under the agreement, the Company is obligated to pay LLS an amount equal to 50% of the cash payments the Company receives from out-licenses and transfers of rights to the product or other liquidity event, as defined in the agreement, until LLS has received an amount equal to 1.5 times the amount of funding the Company receives from LLS. The total amount payable by the Company to LLS will not exceed 3.55 times the amount of funding received from LLS, with the specific amount depending on when the payment(s) occur relative to the timing of the research program and product commercialization. The payments may take the form of cash payments or royalties (not to exceed 5% of net sales) but will not exceed the maximum amount referred to in the preceding sentence.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Basis of consolidation: The consolidated financial statements include the accounts of Celator and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, among other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	New Accounting Pronouncement: In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-10, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminates all incremental financial reporting requirements for development stage entities by removing Accounting Standards Codification (ASC) Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. The amendments in this Update remove the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASC Topic 915 is removed effective for annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of its June 30, 2014 financial statements.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	There were no transfers between levels and the following table provides the assets carried at fair value:
		Fair Value		(Level 1)		(Level 2)		(Level 3)
	June 30, 2014
	Assets:
	Certificates of Deposit	$	14,003,243	$	14,003,243	$	-	$	-
	Money Market Fund		8,308,322		8,308,322		-		-
	Total	$	22,311,565	$	22,311,565	$	-	$	-
	31-Dec-13
	Assets:
	Certificates of Deposit	$	15,003,472	$	15,003,472	$	-	$	-
	Money Market Fund		7,597,730		7,597,730		-		-
	Total	$	22,601,202	$	22,601,202	$	-	$	-

Other_Receivables_Tables

Other Receivables (Tables)	6 Months Ended
	Jun. 30, 2014
Other Receivables, Net, Current [Abstract]	'
Schedule Of Other Receivables And Other Assets [Table Text Block]	'
	Other receivables as of June 30, 2014 and December 31, 2013, consists of the following:
		June 30, 2014		December 31, 2013
	Receivables related to the sale of New Jersey net operating losses	$	-	$	1,412,302
	Other receivables		3,328		5,011
		$	3,328	$	1,417,313

Other_Current_Assets_Tables

Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Schedule of Other Current Assets [Table Text Block]	'
	Other current assets as of June 30, 2014 and December 31, 2013 consist of the following:
		June 30, 2014		December 31, 2013
	Clinical trial materials	$	879,056	$	468,389

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment as of June 30, 2014 and December 31, 2013 including assets held under capital lease, consists of the following:
		June 30, 2014		December 31, 2013
	Computer and equipment	$	140,495	$	136,498
	Furniture and office equipment		96,457		96,457
	Laboratory equipment		1,760,633		1,760,633
	Capital lease equipment		155,523		155,523
	Leaseholds		37,789		37,789
			2,190,897		2,186,900
	Less: Accumulated depreciation		-1,144,411		-1,048,321
		$	1,046,486	$	1,138,579
Schedule Of Depreciation And Amortisation [Table Text Block]	'
		Three months ended				Six months ended
		June 30				June 30
		2014		2013		2014		2013
	Depreciation and amortization	$	48,353	$	49,464	$	96,088	$	97,052

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Payables And Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities as of June 30, 2014 and December 31, 2013 consist of the following:
		June 30, 2014		December 31, 2013
	Accrued bonuses	$	562,392	$	624,472
	Accrued salaries and vacation		176,836		143,484
	Accrued professional fees		30,000		30,911
	Accrued clinical trial expenses		631,023		636,497
	Accrued trade payables other		145,692		195,445
		$	1,545,943	$	1,630,809

Loans_Payable_Tables

Loans Payable (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
	Long-term debt as of June 30, 2014 consists of the following:
	Loan payable	$	10,000,000
	End of term fee		26,660
			10,026,660
	Less: Current portion		-282,253
	Long-term debt	$	9,744,407

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes the activity of the Company’s stock option plans for the six months ended June 30, 2014:
		Number of		Exercise
		options		price
	31-Dec-13	2,578,252		$	2.98
	Granted	478,500			3.15
	Exercised	-42,936			2.34
	Cancelled	-9,269			3.37
	30-Jun-14	3,004,547		$	3.02
	Exercisable at June 30, 2014	1,094,447		$	2.72
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The following table provides information regarding stock options activity during the periods:
		Three months ended							Six months ended
		June 30							June 30
		2014				2013			2014			2013
	Stock compensation expense recognized	$	339,615			$	82,502		$	642,597		$	86,780
	Weighted average grant-date fair value of stock options issued (per share)	$	2.35			$	2.14		$	2.7		$	2.14
	Grant-date fair value of stock options issued	$	197,400			$	3,268,101		$	1,291,950		$	3,268,101
	Volatility		112	%			118.2	%		114.5	%		118.2	%
	Risk-free interest rate		1.9	%			1.9	%		2	%		1.9	%
	Dividend yield		0	%			0	%		0	%		0	%
	Expected life in years		6				6.2			6.2			6.2
	Intrinsic value of stock options exercised	$	-			$	-		$	38,892		$	-

Geographic_Segment_Information1

Geographic Segment Information (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The geographic information about total assets is based on the physical location of the assets.
		Total Assets
		June 30, 2014		December 31, 2013
	United States	$	27,301,017	$	26,190,516
	Canada		242,462		284,563
	Germany		923,877		997,671
	Total Assets	$	28,467,356	$	27,472,750
				Net Loss
		Three months ended				Six months
		June 30				June 30
		2014		2013		2014		2013
	United States		-4,276,673		-3,624,723		-7,931,554		-12,374,358
	Canada		-514,521		-416,254		-1,137,141		-1,350,567
	Total Net Loss	$	-4,791,194	$	-4,040,977	$	-9,068,695	$	-13,724,925

Nature_of_Business_and_Liquidi1

Nature of Business and Liquidity (Details Textual) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Nature Of Business And Liquidity [Line Items]	'	'	'	'
Accumulated deficit	($141,534,065)	($132,465,370)	'	'
Cash and Cash Equivalents, at Carrying Value	$24,924,518	$23,589,516	$31,079,873	$9,648,008

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Assets:	'	'
Total	$22,311,565	$22,601,202
Fair Value, Inputs, Level 1 [Member]	'	'
Assets:	'	'
Total	22,311,565	22,601,202
Fair Value, Inputs, Level 2 [Member]	'	'
Assets:	'	'
Total	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Assets:	'	'
Total	0	0
Certificates of Deposit [Member]	'	'
Assets:	'	'
Certificates of Deposit	14,003,243	15,003,472
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Assets:	'	'
Certificates of Deposit	14,003,243	15,003,472
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Assets:	'	'
Certificates of Deposit	0	0
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Assets:	'	'
Certificates of Deposit	0	0
Money Market Funds [Member]	'	'
Assets:	'	'
Money Market Fund	8,308,322	7,597,730
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Assets:	'	'
Money Market Fund	8,308,322	7,597,730
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Assets:	'	'
Money Market Fund	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Assets:	'	'
Money Market Fund	$0	$0

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Non-cash derivative instrument charge	$0	$747,311	$0	$7,473,108
Fair Value, Inputs, Level 3 [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Non-cash derivative instrument charge	'	$747,311	$7,473,108	'

Other_Receivables_Details

Other Receivables (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Other Receivables [Line Items]	'	'
Receivables related to the sale of New Jersey net operating losses	$0	$1,412,302
Other receivables	3,328	5,011
Other receivables, net	$3,328	$1,417,313

Other_Current_Assets_Details

Other Current Assets (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Other Current Assets [Line Items]	'	'
Clinical trial materials	$879,056	$468,389

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$2,190,897	$2,186,900
Less: Accumulated depreciation	-1,144,411	-1,048,321
Property and equipment, net	1,046,486	1,138,579
Computer and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	140,495	136,498
Furniture and office equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	96,457	96,457
Laboratory equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	1,760,633	1,760,633
Capital lease equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	155,523	155,523
Leaseholds [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$37,789	$37,789

Property_and_Equipment_Details1

Property and Equipment (Details 1) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Depreciation and amortization	$48,353	$49,464	$96,088	$97,052

Property_and_Equipment_Details2

Property and Equipment (Details Textual) (USD $)	3 Months Ended		6 Months Ended					3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Feb. 29, 2012	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
						Scientific Equipment [Member]	Scientific Equipment [Member]	Assets Held for Sale [Member]	Assets Held for Sale [Member]	Assets Held for Sale [Member]
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'
Assets Held For Sale Long Lived	'	'	'	'	$507,622	$74,086	$74,086	'	'	'
Assets Disposals, Written Off Net Book Value	'	'	'	'	'	'	'	'	'	174,768
Proceeds from sale of assets	'	'	0	36,673	'	'	'	'	'	36,673
Loss on disposal of property and equipment	$0	$124,965	$0	$138,692	'	'	'	$0	$0	$138,095

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accrued Liabilities [Line Items]	'	'
Accrued bonuses	$562,392	$624,472
Accrued salaries and vacation	176,836	143,484
Accrued professional fees	30,000	30,911
Accrued clinical trial expenses	631,023	636,497
Accrued trade payables other	145,692	195,445
Accrued liabilities	$1,545,943	$1,630,809

Loans_Payable_Details

Loans Payable (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Schedule Of Loan payable [Line Items]	'	'
Loan payable	$10,000,000	'
End of term fee	26,660	'
Long-term Debt	10,026,660	'
Less: Current portion	-282,253	0
Long-term debt	$9,744,407	$0

Loans_Payable_Details_Textual

Loans Payable (Details Textual) (USD $)	0 Months Ended	3 Months Ended	6 Months Ended
	9-May-14	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
Schedule Of Loan payable [Line Items]	'	'	'	'
Amortization Of Financing Costs And Discounts	'	'	$57,167	$74,752
Adjustments to Additional Paid in Capital, Warrant Issued	'	'	320,752	'
Unamortized Debt Issuance Expense	'	647,498	647,498	'
Line of Credit Facility, Frequency of Payments	'any time between December 15, 2014 and March 31, 2015.	'	'	'
Warrants Maturity Term	'5 years	'	'	'
End of Loan Term, Fees	'	26,660	'	'
Warrant [Member]	'	'	'	'
Schedule Of Loan payable [Line Items]	'	'	'	'
Amortization Of Financing Costs And Discounts	'	30,507	30,507	'
Adjustments to Additional Paid in Capital, Warrant Issued	'	'	0	'
Term Loan [Member]	'	'	'	'
Schedule Of Loan payable [Line Items]	'	'	'	'
Debt Issuance Cost	'	'	357,253	'
End of Term Fee [Member]	'	'	'	'
Schedule Of Loan payable [Line Items]	'	'	'	'
Debt Issuance Cost	'	'	592,500	'
Hercules Technology Growth Capital [Member]	'	'	'	'
Schedule Of Loan payable [Line Items]	'	'	'	'
Line of Credit Facility, Fair Value of Amount Outstanding	10,000,000	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	15,000,000	'	'	'
Line of Credit Facility, Remaining Borrowing Capacity	5,000,000	'	'	'
Long-term Debt, Maturities, Repayment Terms	'repayable in installments over forty-two months including an initial interest-only period of twelve months after closing.	'	'	'
Line of Credit Facility, Interest Rate Description	'Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period extendable to December 1, 2015,	'	'	'
Hercules Technology Growth Capital [Member] | Warrant [Member]	'	'	'	'
Schedule Of Loan payable [Line Items]	'	'	'	'
Stock Issued During Period, Shares, New Issues	158,006	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	2.67	'	'	'
Adjustments to Additional Paid in Capital, Warrant Issued	320,752	'	'	'

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Schedule Of Share Based Compensation Stock Options Activity [Line Items]	'
Number of options, Beginning balance	2,578,252
Number of options, Granted	478,500
Number of options, Exercised	-42,936
Number of options, Cancelled	-9,269
Number of options, Ending balance	3,004,547
Number of options, Exercisable	1,094,447
Exercise price, Beginning balance	$2.98
Exercise price, Granted	$3.15
Exercise pice, Exercised	$2.34
Exercise price, Cancelled	$3.37
Exercise price, Ending balance	$3.02
Exercise price, Exercisable	$2.72

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Stock compensation expense recognized	$339,615	$82,502	$642,597	$86,780
Weighted average grant-date fair value of stock options issued (per share)	$2.35	$2.14	$2.70	$2.14
Grant-date fair value of stock options issued	197,400	3,268,101	1,291,950	3,268,101
Volatility	112.00%	118.20%	114.50%	118.20%
Risk-free interest rate	1.90%	1.90%	2.00%	1.90%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected life in years	'6 years	'6 years 2 months 12 days	'6 years 2 months 12 days	'6 years 2 months 12 days
Intrinsic value of stock options exercised	$0	$0	$38,892	$0

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details Textual) (Non vested Awards [Member], USD $)	6 Months Ended
	Jun. 30, 2014
Non vested Awards [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$4,297,202
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'3 years 1 month 6 days

Geographic_Segment_Information2

Geographic Segment Information (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Total Assets	$28,467,356	'	$28,467,356	'	$27,472,750
Total Net Loss	-4,791,194	-4,040,977	-9,068,695	-13,724,925	'
United States [Member]	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Total Assets	27,301,017	'	27,301,017	'	26,190,516
Total Net Loss	-4,276,673	-3,624,723	-7,931,554	-12,374,358	'
Canada [Member]	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Total Assets	242,462	'	242,462	'	284,563
Total Net Loss	-514,521	-416,254	-1,137,141	-1,350,567	'
Germany [Member]	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Total Assets	$923,877	'	$923,877	'	$997,671

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2014
Princeton University Agreement [Member]	'
Loss Contingencies [Line Items]	'
Agreement termination notice period	'90 days
Rectification of default period	'60 days
Leukemia & Lymphoma Society Agreement [Member]	'
Loss Contingencies [Line Items]	'
Percentage of royalty payable from the amount received from out-licenses and transfers	50.00%
Cash Payment Or Royalties on net sales	5.00%
Leukemia & Lymphoma Society Agreement [Member] | Phase 3 study [Member]	'
Loss Contingencies [Line Items]	'
Funding for project inventions	5,000,000
Leukemia & Lymphoma Society Agreement [Member] | Phase 2 study [Member]	'
Loss Contingencies [Line Items]	'
Funding for project inventions	4,100,000
Vancouver, British Columbia [Member]	'
Loss Contingencies [Line Items]	'
Operating Leases, Future Minimum Payments Due, Total	133,439
Lease Commencement Date	'2013-04-01
Lease Expiration Date	30-Jun-16
Ewing, New Jersey [Member]	'
Loss Contingencies [Line Items]	'
Operating Leases, Future Minimum Payments Due, Total	564,624
Letters of Credit Outstanding, Amount	200,000
Contractual Obligation of letter of credit payment as on December 1, 2014	40,000
Contractual Obligation of letter of credit payment as on December 1, 2015	40,000
Contractual Obligation of letter of credit payment as on December 1, 2016	40,000
Contractual Obligation of letter of credit payment as on December 1, 2017	60,000
Lease Commencement Date	'2013-06-01
Operating Lease Expiration Term	'60 months
British Columbia Cancer Agency [Member]	'
Loss Contingencies [Line Items]	'
Rectification of default period	'45 days
Minimum [Member] | Princeton University Agreement [Member]	'
Loss Contingencies [Line Items]	'
Percentage of royalty payable from the amount received from out-licenses and transfers	45.00%
Minimum [Member] | Leukemia & Lymphoma Society Agreement [Member]	'
Loss Contingencies [Line Items]	'
Number of times amount payable under research funding program	1.5
Maximum [Member] | Princeton University Agreement [Member]	'
Loss Contingencies [Line Items]	'
Percentage of royalty payable from the amount received from out-licenses and transfers	55.00%
Maximum [Member] | Leukemia & Lymphoma Society Agreement [Member]	'
Loss Contingencies [Line Items]	'
Number of times amount payable under research funding program	3.55